Navigation Links
Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
Date:7/31/2008

LOS ANGELES, July 31 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Raptor Pharmaceuticals Corp. "Raptor's drug candidates, which target billion dollar markets, are progressing through the clinic at a rapid pace. The Company will present Phase 2 results for Convivia(TM) sometime in the 3rd quarter of 2008 and we expect FDA approval of Delayed Release (DR) Cysteamine for the treatment of cystinosis in 2010," stated Ross Silver, Director of Research for Vista Partners. For more information and to download the report for free, please visit the Vista Partners website at http://www.vistap.com and click on the "download research" icon.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About Raptor:

Raptor Pharmaceuticals Corp. ("Raptor") is a development-stage biopharmaceutical company leveraging novel drug-targeting platforms and reformulated therapeutics to improve treatment outcomes among patients with liver disorders, infectious diseases, cancer, and various orphan indications. The Company's clinical division advances internally developed and in-licensed clinical-stage product candidates towards marketing approval and commercialization and is currently involved in clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency as part of Raptor's Convivia(TM) program and nephropathic cystinosis as part of Raptor's DR Cysteamine program. Raptor's preclinical division bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins to target cancer, neurodegenerative disorders and infectious diseases. Raptor's preclinical programs include HepTide(TM), WntTide(TM) and NeuroTrans(TM). Bennu executes the clinical development of internal products and in-licensed candidates that are: 1) new chemical entities in mid-to-late stage clinical development; 2) currently approved drugs with potential efficacy in additional indications; and 3) treatments that Bennu could repurpose or reformulate as potentially more effective or convenient treatments for their currently approved indications. For additional information, please visit http://www.raptorpharma.com.

Contact:

Vista Partners LLC

Sherry Watkins

(310)744-5268

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
3. Synvista Therapeutics to Present at the BIO InvestorForum 2007
4. Synvista Therapeutics to be Featured on Wallst.net
5. Provista Awards Agreement to Spheris
6. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
9. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
10. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
11. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events ... announced today. The bold new look is part of a transformation to increase ... a significant growth period. , It will also expand its service offering from its ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks ... Strategy, will speak at the TMA 2017 Annual Meeting , October ... trends in the residential home security market and how smart safety and ... Parks ... "The residential ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
Breaking Biology Technology:
(Date:6/14/2017)...  IBM (NYSE: IBM ) is introducing several innovative ... to developing collaboration between startups and global businesses, taking place ... the event, nine startups will showcase the solutions they have ... France is one ... a 30 percent increase in the number of startups created ...
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):